Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Lilly's Jaypirca recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia across all lines of therapy
What Medicare Part D patients need to know about accessing Foundayo and Zepbound for weight management
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lilly's Jaypirca significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
